The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% higher mortality risk across tumor subtypes. Medscape Medical News
The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% higher mortality risk across tumor subtypes. Medscape Medical News